VK2735 Research: What 1 Studies Show (2026) | RetatrutideCompare

VK2735 — 1 studies indexed on PubMed. Dual GLP-1 / GIP receptor agonist comparable in mechanism to Tirzepatide. Half-life: ~5 days (subcutaneous). FDA status: Investigational (Phase 3 VANQUISH for SC; Phase 2 VENTURE for oral).

PubMed search-result count last fetched 2026-06-18. Records may include reviews, laboratory work, and animal studies; this is not a clinical trial count or a measure of efficacy.

Inspect the PubMed query and results

How many studies have been published on VK2735?

There are approximately 1 studies indexed on PubMed that mention VK2735 (Viking VK2735), based on a search last updated 2026-06-18.

Is VK2735 FDA-approved?

FDA status: Investigational (Phase 3 VANQUISH for SC; Phase 2 VENTURE for oral).

How does VK2735 work?

Dual GLP-1 / GIP receptor agonist comparable in mechanism to Tirzepatide.

Dual GLP-1 / GIP receptor agonist comparable in mechanism to Tirzepatide.

Reference facts

Also known as
Viking VK2735
Category
GLP-1 & Metabolic
Mechanism of action
Dual GLP-1 / GIP receptor agonist comparable in mechanism to Tirzepatide.
Targets
GLP-1R, GIPR
Indications under research or approved
Obesity
Regulatory status (reference entry)
Investigational (Phase 3 VANQUISH for SC; Phase 2 VENTURE for oral)
Half-life
~5 days (subcutaneous)
Sequence notes
Dual GLP-1 / GIP receptor agonist available in subcutaneous (weekly) and oral tablet formulations.
Originator / sponsor
Viking Therapeutics
First reported
2023

Primary References

Explore research articles about VK2735

This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.